FMA
REGN icon

FNY Managed Accounts’s Regeneron Pharmaceuticals REGN Stock Holding History

FNY Managed Accounts’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-362
Closed -$140K – 519
2017
Q1 		$140K Buy
+362
New +$134K 0.43% 41
2016
Q4 		– Sell
-200
Closed -$80.4K – 222
2016
Q3 		$80.4K Buy
+200
New +$80.2K 0.07% 168

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

FNY Managed Accounts's REGN Position: Q2 2017 in Review

FNY Managed Accounts sold out of Regeneron Pharmaceuticals (REGN) in Q2 2017, closing a stake of 362 shares — an estimated $140K sold.

FNY Managed Accounts first reported a position in REGN in Q3 2016 and held it in 2 quarters. The position peaked at $140K in Q1 2017. 603 funds tracked by Wall St. Rank hold REGN as of Q2 2017.

  • FNY Managed Accounts reported no remaining Regeneron Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 362 Regeneron Pharmaceuticals shares in Q2 2017, an estimated $140K.
  • FNY Managed Accounts first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • FNY Managed Accounts's Regeneron Pharmaceuticals position peaked at $140K in Q1 2017.
  • 603 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.